AGILeBiotics is developing novel next-generation aminoglycoside antibiotics for the treatment of multi-drug resistant (MDR) Gram-negative infections associated to high death rates, i.e. hospital-acquired-/ventilator-associated pneumonia (HAP/VAP), bloodstream infections (BSI) and neonatal sepsis. Our main focus is to find new antibiotic candidates active against carbepenem-resistant Enterobacteriaceae (CRE). In addition, AGILeBiotics is motivated to find novel treatment options for MDR tuberculosis and cystic fibrosis.

In August 2019,  Toframicin (ABX-605) has been selected for pre-clinical development, i.e. CMC and GLP-toxicity studies. The pre-clinical candidate is a semi-synthetic aminoglycoside with the following features:
(1) Toframicin tackles class-related antibacterial resistance mediated by aminoglycoside modifying enzymes. 
(2) It shows exceptional in vitro activity against Gram-negative clinical isolates of  XDR/MDR Pseudomonas aeruginosa, Acinetobacter baumanniicarbapenem-resistant Enterobacteriaceae strains. 
(3) The candidate has exceptional in vitro activity against Gram-positive clinical isolates of multidrug-resistant MRSA and VRE strains.

(4) With increased in vivo efficacy (demonstrated in two models) compared to other aminoglycosides and reduced toxicity Toframicin has the potential to become a low-dose antibiotic with increased therapeutic index.
(5) Toframicin has a significantly reduced propensity for resistance development compared to other semi-synthetic aminoglycosides, such as Amikacin.